ATIC and cancer: Because both catalytic activities are essential for purine biosynthesis in cancer cells, three different strategies can be used to target ATIC for anti-cancer treatment: (1) selective inhibition of IMPCHase activity; (2) selective inhibition of AICAR TFase activity; and (3) the inhibition of AICAR TFase activity by preventing monomeric dimerization.